While AOD 9604 targets your metabolism directly, GLP-1s affect appetite and insulin signaling, with no overlap between the two
This comprehensive approach may offer benefits single-target medications cannot achieve
This 5:1:1:1 ratio is not arbitrary
They are unapproved compounded products, prepared by compounding pharmacies, which have not been reviewed by the FDA for safety, efficacy or quality in this indication
The clinical trial protocol explicitly allowed for delayed escalation based on tolerability
Interestingly, PNPLA3 I148M is not properly targeted by the UPS which likely promotes the disease-causing variant to accumulate on LDs (135) where it can disrupt protein-protein interactions critical for TAG hydrolysis (70, 75)